Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 ConferenceGlobeNewsWire • 02/05/24
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment' on Strategy for Improved Neoantigen Immunogenicity PredictionGlobeNewsWire • 12/18/23
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent HighlightsGlobeNewsWire • 11/13/23
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementGlobeNewsWire • 09/22/23
Are Medical Stocks Lagging Achilles Therapeutics (ACHL) This Year?Zacks Investment Research • 09/22/23
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/04/23
Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/10/23
Achilles Therapeutics' New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell AntigensGlobeNewsWire • 05/10/23
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA StatusGlobeNewsWire • 04/25/23
Achilles Therapeutics to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing SummitGlobeNewsWire • 04/17/23
Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business HighlightsGlobeNewsWire • 03/07/23
Is Achilles Therapeutics (ACHL) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 02/02/23
Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/20/22
Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022GlobeNewsWire • 12/06/22
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022GlobeNewsWire • 11/30/22
Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary MethodGlobeNewsWire • 11/22/22
Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/08/22
What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy StockZacks Investment Research • 11/01/22
Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell TherapyGlobeNewsWire • 10/06/22
Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/09/22
Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy ManufacturingGlobeNewsWire • 07/21/22
Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory BoardGlobeNewsWire • 06/30/22